source
- Legend Biotech reports first in vivo CAR-T data from Chinese lymphoma trialLegend Biotech has released its first in vivo CAR-T cell therapy data, marking the next step after its CAR-T product Carvykti. The data come from an investigator-initiated trial in China that enro…
- Celcuity reports combo regimen with gedatolisib doubles progression‑free survival odds in late‑stage breast cancerCelcuity announced at ASCO 2026 that its experimental drug gedatolisib, used in a combination regimen, showed a significant improvement in a late‑stage breast cancer trial. The data revealed that…